Skip to main content

Table 3 Vaginal fungal burden in different treatment group (Log CFU mL-1 ± SD and number of infected rabbits /original infected rabbits, n = 5 per group)

From: Low intensity ultrasound-mediated drug-loaded nanoparticles intravaginal drug delivery: an effective synergistic therapy scheme for treatment of vulvovaginal candidiasis

Group

0 day (%)

3 day (%)

7 day (%)

Control

3.661 ± 0.010 (N 5/5, 100)

3.367 ± 0.039 (N 5/5, 100)

3.278 ± 0.220 (N 5/5, 100)

US

3.630 ± 0.036 (N 5/5, 100)

3.428 ± 0.018 (N 5/5, 100)

3.227 ± 0.029 (N 5/5, 100)

AmB

3.628 ± 0.047 (N 5/5, 100)

3.897 ± 0.048 (N 5/5, 100)

2.114 ± 0.530* (N 4/5, 100)

US + AmB

3.643 ± 0.010 (N 5/5, 100)

2.690 ± 0.081 (N 4/5, 80)

1.513 ± 0.223* (N 2/5, 40)

AmB-NPs

3.632 ± 0.045 (N 5/5, 100)

2.939 ± 0.063 (N 4/5, 80)

1.820 ± 0.124* (N 3/5, 60)

US + AmB-NPs

3.642 ± 0.041 (N 5/5, 100)

1.325 ± 0.297* (N 2/5, 40)

0.159 ± 0.275** (N 1/5, 20)

  1. *P < 0.05, **P < 0.01